Additive gastrointestinal effects : Tirzepatide commonly causes nausea, vomiting, diarrhea, and constipation, particularly during dose escalation
But there are definitely things you can change or at least watch out for to minimize the risk of developing this type of condition
Cetaruk EW, Dart RC, Hurlbut KM, Horowitz RS, Shih R
A study of a few dozen participants over several weeks cannot reliably rule out uncommon harms or long-term effects
Data on kidney outcomes remain limited, but SGLT2is appear particularly effective when kidney protection is the primary goal, regardless of concurrent treatment
Evaluation of risk factors for insulin resistance: a cross sectional study among employees at a private university in Lebanon